Sara Tolaney from Dana-farber
, what's new in breast cancer CDK 4/6 inhibitor in adjuvant setting, 34% reduction in recurrence
SERDs elacestrant for ESR1 mutated mHR+ breast cancer, adjuvant trial ongoing
AKT inhibitor (Capivsertib)+ fulvestrant coming soon
Oral anti-Her2 agent: tucatinib
ADC Saci, T-Dxd
IO: Pembrolizumab for stage IV breast ca (PD-L1 CPS>=10%), neoadjuvant for TNBC regardless PD-L1 status, pCR rate in 60%
